Thermo Fisher Scientific Inc. $TMO Shares Acquired by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,119 shares of the medical research company’s stock after purchasing an additional 1,284 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $2,365,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Highline Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares in the last quarter. Cloud Capital Management LLC acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $31,000. Capital A Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after purchasing an additional 66 shares in the last quarter. Elevation Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 35.1% in the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Finally, Howard Hughes Medical Institute purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $33,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 32,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total value of $18,668,480.00. Following the completion of the sale, the chief operating officer owned 65,480 shares in the company, valued at approximately $38,200,377.20. The trade was a 32.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Frederick M. Lowery sold 6,913 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the transaction, the executive vice president owned 14,367 shares in the company, valued at approximately $8,586,868.56. This trade represents a 32.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 114,292 shares of company stock worth $66,518,754. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $543.46 on Monday. The company has a market capitalization of $204.18 billion, a price-to-earnings ratio of 30.63, a price-to-earnings-growth ratio of 3.13 and a beta of 0.93. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The stock has a 50 day moving average price of $590.76 and a 200 day moving average price of $543.42.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the previous year, the firm earned $6.10 EPS. The company’s revenue was up 7.2% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. TD Cowen reduced their price target on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Citigroup upped their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $633.68.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.